证券之星消息，截至2026年2月27日收盘，蓝帆医疗(002382)报收于6.08元，上涨1.16%，换手率 1.14%，成交量11.35万手，成交额6897.48万元。 2月27日的资金流向数据方面，主力资金净流入512.73万元，占总成交额7.43%，游资资金净流入344.74 万元，占总成交额5.0%，散户资金净流出857.47万元，占总成交额12.43%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 蓝帆医疗2025年三季报显示，前三季度公司主营收入41.82亿元，同比下降10.15%；归母净利润-2.86亿 元，同比下降30.09%；扣非净利润-3.64亿元，同比下降46.25%；其中2025年第三季度，公司单季度主 营收入14.01亿元，同比下降15.02%；单季度归母净利润-1.51亿元，同比下降153.64%；单季度扣非净利 润-1.55亿元，同比下降151.16%；负债率41.01%，投资收益1348.2万元，财务费用1.4亿元，毛利率 13.66%。蓝帆医疗（002382）主营业务：心脑血管业务、健康防护业务、应急救护业务、新营销业 务。 资金流向名词解释：指通过价格变化反 ...

近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 蓝帆医疗2025年三季报显示，前三季度公司主营收入41.82亿元，同比下降10.15%；归母净利润-2.86亿 元，同比下降30.09%；扣非净利润-3.64亿元，同比下降46.25%；其中2025年第三季度，公司单季度主 营收入14.01亿元，同比下降15.02%；单季度归母净利润-1.51亿元，同比下降153.64%；单季度扣非净利 润-1.55亿元，同比下降151.16%；负债率41.01%，投资收益1348.2万元，财务费用1.4亿元，毛利率 13.66%。蓝帆医疗（002382）主营业务：心脑血管业务、健康防护业务、应急救护业务、新营销业 务。 证券之星消息，截至2026年2月12日收盘，蓝帆医疗(002382)报收于5.81元，下跌1.86%，换手率 0.85%，成交量8.53万手，成交额4982.41万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量 ...

Core Viewpoint - Bluefan Medical (002382) has reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical's main revenue was 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit excluding non-recurring items was -364 million yuan, reflecting a decline of 46.25% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a significant drop of 153.64% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stood at 41.01% [2]. - Investment income was reported at 13.482 million yuan, while financial expenses amounted to 140 million yuan [2]. - The gross profit margin was 13.66% [2]. Market Activity - As of February 9, 2026, Bluefan Medical's stock closed at 6.02 yuan, with an increase of 0.84% [1]. - The turnover rate was 0.95%, with a trading volume of 94,600 hands and a transaction value of 56.912 million yuan [1]. - On February 9, the net inflow of main funds was 1.728 million yuan, accounting for 3.04% of the total transaction value [1]. - The net inflow of speculative funds was 1.7175 million yuan, representing 3.02% of the total transaction value [1]. - Retail investors experienced a net outflow of 3.4455 million yuan, which was 6.05% of the total transaction value [1].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit after deducting non-recurring items was -364 million yuan, reflecting a significant decline of 46.25% [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a drastic decline of 153.64% [2]. - The single-quarter net profit after deducting non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stands at 41.01%, with investment income of 13.482 million yuan and financial expenses of 140 million yuan [2]. - The gross profit margin is reported at 13.66% [2]. Market Activity - As of February 6, 2026, Bluefan Medical's stock closed at 5.97 yuan, with an increase of 1.19% [1]. - The trading volume was 86,300 hands, with a total transaction amount of 51.478 million yuan [1]. - On February 6, the net inflow of main funds was 3.8895 million yuan, accounting for 7.56% of the total transaction amount [1]. - The net inflow of speculative funds was 1.1186 million yuan, representing 2.17% of the total transaction amount [1]. - Retail investors experienced a net outflow of 5.0081 million yuan, which is 9.73% of the total transaction amount [1].

Core Viewpoint - Bluefan Medical (002382) has shown a slight increase in stock price, but the company is facing significant financial challenges, including declining revenues and profits [1][3]. Financial Performance - As of January 15, 2026, Bluefan Medical's stock closed at 6.03 yuan, with a 0.67% increase and a trading volume of 205,700 hands, amounting to a total transaction value of 125 million yuan [1]. - In the past five days, the company has experienced fluctuations in net capital flow, with a net inflow of 7.82 million yuan from main funds on January 15, 2026, which accounted for 6.24% of the total transaction value [2]. - The company's total market capitalization is 6.073 billion yuan, with a net asset value of 9.707 billion yuan, but it reported a net profit of -286 million yuan, ranking last in the industry [3]. Revenue and Profit Trends - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15%, and a net profit attributable to shareholders of -286 million yuan, down 30.09% year-on-year [3]. - In Q3 2025 alone, the company recorded a main revenue of 1.401 billion yuan, a decline of 15.02% compared to the same quarter the previous year, and a net profit of -151 million yuan, a staggering drop of 153.64% [3]. Industry Comparison - Bluefan Medical's gross profit margin stands at 13.66%, significantly lower than the industry average of 50.62%, placing it in the 122nd position out of 126 companies in the medical device sector [3]. - The company's return on equity (ROE) is -3.56%, which is also below the industry average of 0.23%, ranking 119th out of 126 [3].

Core Viewpoint - As of December 30, 2025, BluFan Medical (002382) reported a closing price of 5.51 yuan, down 1.25%, with a turnover rate of 0.67% and a trading volume of 67,300 hands, amounting to a transaction value of 37.29 million yuan [1] Financial Performance - For the first three quarters of 2025, BluFan Medical's main revenue was 4.182 billion yuan, a year-on-year decrease of 10.15% - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year - The net profit excluding non-recurring gains and losses was -364 million yuan, a decline of 46.25% year-on-year - In Q3 2025, the company's single-quarter main revenue was 1.401 billion yuan, a year-on-year decrease of 15.02% - The single-quarter net profit attributable to shareholders was -151 million yuan, a significant decline of 153.64% year-on-year - The single-quarter net profit excluding non-recurring gains and losses was -155 million yuan, down 151.16% year-on-year - The company's debt ratio stood at 41.01%, with investment income of 13.48 million yuan and financial expenses of 140 million yuan, resulting in a gross profit margin of 13.66% [2] Capital Flow - On December 30, 2025, the capital flow data indicated a net inflow of 915,100 yuan from main funds, accounting for 2.45% of the total transaction value - Retail investors experienced a net outflow of 1.8907 million yuan, representing 5.07% of the total transaction value - The capital flow analysis is based on price changes to infer the direction of funds, with inflows defined by rising prices and outflows by falling prices [1][2]

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Group 1: Stock Performance - As of December 4, 2025, Bluefan Medical's stock closed at 5.46 yuan, down 2.5% with a turnover rate of 0.86% and a trading volume of 85,600 hands, amounting to a total transaction value of 47.07 million yuan [1]. - The net outflow of main funds on December 4 was 6.0374 million yuan, accounting for 12.83% of the total transaction value, while retail investors saw a net inflow of 3.9286 million yuan, representing 8.35% of the total [1]. Group 2: Recent Fund Flow - Over the past five days, the stock has shown a consistent trend of net outflows from main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan, which was 32.24% of the total transaction value [2]. - The net inflow from retail investors peaked on December 2 at 8.4658 million yuan, which was 21.09% of the total transaction value for that day [2]. Group 3: Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15%, and a net profit attributable to shareholders of -286 million yuan, down 30.09% [3]. - The company's gross profit margin stands at 13.66%, significantly lower than the industry average of 51.22%, indicating a challenging competitive position [3]. - The company's total market capitalization is 5.499 billion yuan, with a net asset value of 9.707 billion yuan, ranking 63rd in the industry [3].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of December 3, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.71% with a trading volume of 69,300 shares and a turnover of 38.97 million yuan [1]. - The company reported a total revenue of 4.182 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.15% [3]. - The net profit attributable to shareholders was -286 million yuan, a decline of 30.09% year-on-year [3]. - The third quarter alone saw a revenue of 1.401 billion yuan, down 15.02% year-on-year, and a net profit of -151 million yuan, a staggering decline of 153.64% [3]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 11.01 billion yuan, ranking 63rd out of 124 in the medical device sector [3]. - The company's net asset value stands at 9.707 billion yuan, which is above the industry average of 3.893 billion yuan, ranking 7th [3]. - The price-to-earnings ratio is -14.79, while the industry average is 60.46, indicating a negative earnings situation [3]. - The gross margin is 13.66%, significantly lower than the industry average of 51.22%, ranking 121st [3]. Capital Flow - On December 3, 2025, the net outflow of main funds was 3.1814 million yuan, accounting for 8.16% of the total turnover [1][2]. - Retail investors showed a net inflow of 5.2753 million yuan, representing 13.54% of the total turnover on the same day [1][2]. - Over the past five days, the trend shows a consistent outflow of main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan [2].

Core Viewpoint - Bluefan Medical (002382) has shown a decline in stock price and financial performance, with significant net losses reported in recent quarters, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of November 28, 2025, Bluefan Medical's stock closed at 5.73 yuan, down 0.35%, with a trading volume of 76,600 hands and a transaction value of 43.58 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the company's main revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market value is 5.771 billion yuan, significantly lower than the industry average of 11.144 billion yuan, ranking 62 out of 124 in the medical device sector [3]. - The company's net asset stands at 9.707 billion yuan, ranking 7 in the industry, while its net profit is the lowest in the sector at -2.86 billion yuan, ranking 124 [3]. - The company's price-to-earnings ratio is -15.14, and its price-to-book ratio is 0.75, indicating a low valuation compared to the industry average [3]. Capital Flow - On November 28, 2025, the net inflow of main funds was 711,400 yuan, accounting for 1.63% of the total transaction value, while retail investors saw a net outflow of 2.1339 million yuan, representing 4.9% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from retail investors on multiple days [2].

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in terms of stock price and financial metrics, with a notable decline in revenue and profit margins in recent quarters [1][3]. Financial Performance - As of November 12, 2025, Bluefan Medical's stock closed at 5.82 yuan, up 0.87% with a trading volume of 139,000 shares and a transaction value of 81.01 million yuan [1]. - The company reported a total revenue of 4.182 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.15% [3]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year, with a net profit margin of -7.24% [3]. - The third quarter alone saw a revenue of 1.401 billion yuan, a decline of 15.02% year-on-year, and a net profit of -151 million yuan, a staggering drop of 153.64% [3]. Market Position - Bluefan Medical's total market capitalization is 5.862 billion yuan, ranking 62nd in the medical device industry, which has an average market cap of 11.669 billion yuan [3]. - The company has a price-to-earnings ratio of -15.37, significantly lower than the industry average of 60.71, indicating challenges in profitability [3]. - The company's gross margin stands at 13.66%, compared to the industry average of 51.22%, placing it at 121st in the industry ranking [3]. Capital Flow - On November 12, 2025, the net outflow of main funds was 4.1047 million yuan, accounting for 5.07% of the total transaction value, while retail investors saw a net inflow of 2.8734 million yuan, representing 3.55% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from different investor categories [2].